United States Patent 10,159,683 (US10159683): Scope and Claim-by-Claim Analysis of Dexamethasone–Triethyl Acetyl Citrate Eye Inflammation Kits and Unit Doses
US 10,159,683 claims a narrow, kit-based and unit-dose delivery concept for treating ocular inflammation (with explicit administration post-cataract surgery) using a dexamethasone / triethyl acetyl citrate formulation with tightly defined w/w ratios, fill volumes, and dexamethasone mass per unit dose. The estate’s practical protection is concentrated on (i) the specific excipient-dex formulation essentiality, (ii) 5 µL-scale anterior chamber dosing, and (iii) the kit’s dose-loading and dose-delivery guide components.
What does US 10,159,683 claim for ophthalmic inflammation treatment kits?
Independent claim 1: A “kit” with specific formulation essentiality and device set
Claim 1 is an apparatus-and-composition combination. It requires all of the following:
- Kit for treatment of inflammation in the eye
- A vial containing a formulation consisting essentially of:
- dexamethasone
- triethyl acetyl citrate
- w/w ratio of dexamethasone:triethyl acetyl citrate is selected from:
- about 6:94
- about 9:91
- about 12:88
- A set of administration components:
- injection syringe
- needle
- cannula
- dose loading guide
- dose delivery guide
Key scope drivers
- “Consisting essentially of” is central: it allows minor components that do not materially alter the basic and novel characteristics, but it locks the formulation to dexamethasone + triethyl acetyl citrate as the core actives/excipients relationship. Competitors seeking design-arounds often try to introduce a different principal solubilizer or stabilize excipient such that the formulation no longer “consists essentially of” the specified excipient system.
- The kit is not just a syringe with a drug. It includes dose loading and dose delivery guides, which narrows literal infringement to kits containing that specific structural/functional set.
Dependent claim set: volume, concentration, and delivery into the anterior chamber
- Claims 2–3 narrow the dose-loading guide to load about 4–6 µL, and specifically about 5 µL.
- Claim 4 narrows concentration to about 9% w/w dexamethasone / 91% w/w triethyl acetyl citrate.
- Claim 6 adds the instructional content and an explicit regimen: single unit dose of ~5 µL into the anterior chamber after cataract surgery.
Practical effect: even though claim 1 broadly captures three formulation ratios, the later dependent claims pull the protection toward the 9:91 concentration and the post-cataract anterior chamber dosing workflow at ~5 µL.
How broad is claim 1 versus the narrower concentration and unit-dose claims?
Claim 1 breadth
Claim 1 covers:
- Any kit meeting the defined drug/excipient “essentially consisting of” and the three ratio options.
- Any dose-loading/delivery guide functionality so long as they are part of the kit, without specifying a 5 µL volume in claim 1 itself (that appears in dependent claims).
So, claim 1 breadth is mostly constrained by:
- the three ratio bands
- the presence of dose loading + dose delivery guides
- the defined components (vial, syringe, needle, cannula, guides)
Claims 7–10: unit dosage form at 4–6 µL with essential composition
Claim 7 claims a unit dosage form rather than a kit. It requires:
- about 4–6 µL of composition
- composition consisting essentially of:
- about 9% (w/w) dexamethasone
- about 91% (w/w) triethyl acetyl citrate
Claim 8 then fixes volume to about 5 µL.
Claim 9 and 10 quantify dexamethasone mass:
- 342–697 µg dexamethasone in the unit dose
- specific embodiment: about 517 µg
Scope note: claims 7–10 remove the device list and focus infringement analysis on:
- whether the delivered composition is “consisting essentially of” the specific dexamethasone/triethyl acetyl citrate system, and
- whether the unit dose is in the 4–6 µL and 342–697 µg mass envelope.
Claims 11–14: injection syringe as the unit dosage form carrier
Claim 11 recasts the unit dosage form as:
- an injection syringe containing 4–6 µL of the specified composition.
Claims 12–14 then mirror claims 8–10:
- volume about 5 µL
- dexamethasone dose 342–697 µg
- specific embodiment 517 µg
Practical effect: if a competitor packages the same formulation and fill volume inside a prefilled syringe (even without the full kit components of claim 1), claims 11–14 are the more direct infringement targets.
What formulation limitations are imposed by “consisting essentially of” dexamethasone and triethyl acetyl citrate?
What must be in the formulation
Across all claims, the formulation is limited to:
- dexamethasone
- triethyl acetyl citrate
and is described as consisting essentially of those components. The “essentially” qualifier is legally meaningful:
- It creates room for non-material excipients but not for a formulation design that materially changes the character, such as substituting a different solubilizer system or altering the nature of the carrier in a way that a court finds materially different from what the patent claims as essential.
Which ratios are explicitly claimed
The ratios are locked into:
- about 6:94, 9:91, or 12:88 (claim 1)
Then claim 4 specifically claims:
- about 9% w/w dexamethasone and about 91% w/w triethyl acetyl citrate
How much dexamethasone per unit is claimed
Claims 9–10/13–14 add a dosage-mass constraint:
- 342–697 µg dexamethasone per 4–6 µL unit dose
- about 517 µg for the ~5 µL embodiment
This converts formulation percentage into mass reality and tightens infringement exposure for any alternate fill-volume/dilution strategy.
What is the dosing geometry: dose volume, anterior chamber delivery, and post-cataract instructions?
Dose-loading guide limits (claims 2–3)
- Dose loading guide designed to load ~4–6 µL
- specific: designed to load ~5 µL
If a device does not load within this envelope, claim 2 and claim 3 may not be met. However, claim 1 could still be asserted if it only requires the presence of dose loading/delivery guides (without volume in claim 1).
Administration instruction and surgical context (claim 6)
Claim 6 requires instructions for:
- administration of a single unit dose
- ~5 µL into the anterior chamber
- following cataract surgery
This is a functional and informational limitation. It narrows how and for what indication a kit is marketed and how directions are provided. A competitor with materially different route, different timing, or different surgical context may be able to avoid this dependent claim even if the formulation itself matches.
What is the patent landscape risk around US 10,159,683 given these claim boundaries?
What competitors will design around first
The claim language suggests the most straightforward engineering risk points:
- Excipient system swap: replacing triethyl acetyl citrate with another solubilizer/emulsion vehicle to avoid “consisting essentially of” language.
- Ratio shift: using a dexamethasone:triethyl acetyl citrate ratio outside the three claimed ratio options.
- Fill-volume shift: moving away from 4–6 µL and especially the “about 5 µL” embodiment.
- Mass-per-dose shift: changing concentration or volume so dexamethasone mass per syringe falls outside 342–697 µg, and especially outside ~517 µg.
- Device/kit composition: omitting dose loading guide and dose delivery guide from the product kit set (relevant to claim 1).
Where infringement may still occur despite design changes
Even if a competitor changes some device parts, infringement may be captured by claims 7–10 (unit dose composition) or claims 11–14 (prefilled syringe unit dosage), provided the competitor’s filled composition is still “consisting essentially of” dexamethasone and triethyl acetyl citrate and matches the unit dose constraints.
How does claim architecture affect enforcement and licensing leverage?
Independent claim 1 vs. unit-dose claims 7 and 11
- Claim 1 targets an end-to-end kit with specific device components and defined formulation ratios.
- Claims 7 and 11 target the composition in a unit dose form, with defined volume and dexamethasone mass constraints.
This creates two enforcement vectors:
- Packaging and workflow infringement (kit + guides + specific dose geometry).
- Drug product container infringement (prefilled unit dosage in a syringe).
A license negotiation can leverage both vectors: a generic or competitor can’t easily avoid risk by altering only packaging if the formulation-in-syringe matches the specified mass and volume.
Which elements are likely to be litigated: formulation scope and measurement precision?
Based on the claim language, the main factual disputes in an infringement case would typically center on:
- Whether a competitor’s formulation is still “consisting essentially of” dexamethasone and triethyl acetyl citrate (i.e., whether other excipients are materially altering the claimed essential characteristics).
- Whether the competitor’s w/w ratio lands within “about” ranges for the claimed options (6:94, 9:91, 12:88) and whether the concentration aligns with the 9/91 dependent claim.
- Whether the delivered volume is designed to be about 5 µL and within 4–6 µL.
- Whether the dexamethasone mass per unit is within 342–697 µg and about 517 µg for the central embodiment.
- For claim 6, whether the product instructions tie the regimen to single-dose anterior chamber delivery after cataract surgery.
What claim coverage exists for alternative ratio formulations or different fill volumes?
Ratio alternatives (claim 1 only)
Claim 1 covers three ratio selections. If a competitor uses:
- 9:91, it overlaps claim 1 and claim 4 concentration, and likely overlaps claims 7–14 if other unit constraints are met.
- 6:94 or 12:88, it still potentially overlaps claim 1 but does not meet the dependent concentration claim 4, and likely misses the 9/91 unit dosage claims 7–10 and 11–14.
Fill volume changes
- Claims 2–3 and 8–10/12–14 anchor to ~5 µL.
- Claims 7/9 allow 4–6 µL with mass band 342–697 µg.
A competitor moving to smaller or larger fill volumes could avoid multiple dependent claims, but claim 1 still covers kits without volume in the independent claim itself. In practice, if the kit product is designed around the same dose geometry, the dependent claims will be the most relevant.
Does the patent protect the dosing method, the regimen, or only device kits?
This patent primarily protects:
- a kit configuration (claim 1), including device components and guides
- a unit dosage form/prefilled syringe (claims 7–14)
- an instructional regimen tied to post-cataract anterior chamber administration (claim 6)
It does not read as a broad medical method claim covering all steroid dosing for ocular inflammation. The explicit limitation to cataract surgery, anterior chamber, and a single ~5 µL unit dose places the protected “method” in claim 6 into a packaging/instruction context rather than a free-standing therapeutic protocol.
Key Takeaways
- US 10,159,683 is built around a specific dexamethasone + triethyl acetyl citrate essential formulation system and a tight ophthalmic delivery geometry (about 4–6 µL, centered on ~5 µL; dexamethasone mass about 342–697 µg; anterior chamber after cataract surgery).
- The enforceable scope splits into:
- Kit/device set coverage (claim 1) requiring vial + syringe + needle + cannula + dose loading guide + dose delivery guide.
- Unit dosage/prefilled syringe coverage (claims 7–10 and 11–14) focused on fill volume, w/w composition, and delivered dexamethasone mass.
- The fastest design-around levers are likely excipient-system substitution, ratio displacement outside 6:94, 9:91, 12:88, and move away from ~5 µL and ~517 µg.
FAQs
-
What does “consisting essentially of dexamethasone and triethyl acetyl citrate” mean for potential generic formulations?
It constrains infringement to products whose composition does not materially alter the essential character defined by the dexamethasone/triethyl acetyl citrate system.
-
If a competitor matches the ratio but changes fill volume, which claims are most at risk?
Claims 7–10 and 11–14 are most volume sensitive (4–6 µL; about 5 µL). Claim 1 remains more resilient because it is not volume-limited in the independent claim.
-
Does claim 6 create additional infringement risk tied to cataract surgery packaging and labeling?
Yes. Claim 6 requires instructions for single-unit ~5 µL into the anterior chamber following cataract surgery.
-
Can infringement occur without a full kit containing both loading and delivery guides?
Yes, potentially under the unit dosage form and prefilling claims (7–10 and 11–14) if the composition and unit dose geometry match.
-
Which parameter is most likely to be decisive in nonclinical testing disputes: ratio, volume, or dexamethasone mass?
Dexamethasone mass per unit dose and actual delivered volume are typically the most concrete for testing and claim element matching, with ratio serving as a formulation characterization cross-check.
References
- United States Patent US 10,159,683. “Kit for Treatment of Inflammation in the Eye Using Dexamethasone and Triethyl Acetyl Citrate” (claims provided by user).
